

2018 MID-ATLANTIC CONFERENCE

8th ANNUAL CURRENT CONCEPTS IN **VASCULAR THERAPIES**



Medical Management of Venous Ulcers When a Vascular Consult Isn't Enough

Michael F. Amendola MD FACS
Hunter Holmes McGuire VA Medical Center
Virginia Commonwealth University Health System

2018 MID-ATLANTIC CONFERENCE

8th ANNUAL CURRENT CONCEPTS IN **VASCULAR THERAPIES**



“Non-Surgical” Management of Venous Ulcers When a Vascular Consult Isn’t Enough

Michael F. Amendola MD FACS
Hunter Holmes McGuire VA Medical Center
Virginia Commonwealth University Health System


Disclaimer

- Although the information contained in this session is focused on a disease state with details as it pertains to practice in the Department of Veterans Affairs, it is not intended to provide interpretation of VA policy nor specific details about how individual VA Medical Centers operate services within their jurisdiction.
- The contents do not represent the views of the United States Department of Veterans Affairs nor the United States Government.



Outline

- General Philosophy
- Common Ground
- Components of Non-Operative Management
- Food for Thought
- Conclusions






WHO YA GONNA CALL?



GHSTBUSTERS****

COMMON GROUND




Hydrostatic



Weight of the column of blood from
the right atrium to the foot









Hydrodynamic


Related to the pressures generated
by contractions of the skeletal
muscles of the leg in the capillary
network
















Venous
Insufficiency





Pathogenesis


- Disrupting of microcirculation
- Increasing permeability
- Leakage of plasma and erythrocytes into the surrounding tissue
- Increased levels of leukocytes in the dependent limbs of patients with chronic venous insufficiency




- Franzeck UK, Bollinger A, Huch R, Huch A. Transcutaneous oxygen tension and capillary morphologic characteristics and density in patients with chronic venous incompetence. *Circulation* 1984;70:806–811.
- Mourad MM, Barton SP, Marks R. Changes in endothelial cell mass, luminal volume and capillary number in the gravitational syndrome. *Br J Dermatol* 1989;121:447–461
- Butler CM, Coleridge Smith PD. Microcirculatory aspects of venous ulceration. *J Dermatol Surg Oncol* 1994;20:474–480.
- Burnand KG, Whimster I, Naidoo A, Browse NL. Pericapillary fibrin in the ulcer-bearing skin of the leg: the cause of lipodermatosclerosis and venous ulceration. *BMJ* 1982;285:1071–1072
- Thomas PR, Nash GB, Dormandy JA. White cell accumulation in dependent legs of patients with venous hypertension: a possible mechanism for trophic changes in the skin. *BMJ* 1988;296:1693–1695

White Cell Trapping

- Localized hypertension → leukocyte trapping/activation
- Releasing free radicals and promotes cell death/tissue damage
- Capillary bed hypertension macromolecules leaking in dermis
- Traps growth factors and cytokines necessary for tissue repair



Fibrin Cuff Theory







- Pericapillary fibrin cuffs that result from venous hypertension
- Extravasation of fibrinogen
- Barriers to the diffusion
- Leading to tissue hypoxia, cell death and ulceration
- However ✎ discontinuous, and ulcers can heal





Clinical Classification

C0	No visible sign of venous disease
C1	Telangiectases and/or reticular veins
C2	Varicose veins
C3	Edema
C4 [‡]	Changes in skin and subcutaneous tissue
A	Pigmentation or eczema
B	Lipodermatosclerosis or atrophie blanche
C5	Healed ulcer
C6	Active ulcer







NON-OPERATIVE MANAGEMENT



NUTRITION

ACTIVITY

COMPRESSION

NON-OPERATIVE
MANAGEMENT

INFECTION
CONTROL

WOUND CARE

MEDICAL
MANAGEMENT



NUTRITION

ACTIVITY

COMPRESSION

NON-OPERATIVE
MANAGEMENT

INFECTION
CONTROL

WOUND CARE

MEDICAL
MANAGEMENT





NUTRITIONAL



The Effect of Weight

- Obese increases the risk of chronic venous disease and varicose veins
- 🖱️ reduces pressure on leg veins
- 🖱️ micro-circulation
- 🖱️ energy
- 🖱️ mobility




- Fort F. Venous Insufficiency, Chronic. In: Ferri FF, ed. Ferri's Clinical Advisor 2017: Elsevier, Inc.; 2017b.
- Eberhardt RT, Raffetto JD. Chronic venous insufficiency. *Circulation*. Jul 22 2014;130(4):333-346.
- NIH. National Heart, Lung, and Blood Institute. Who Is at Risk for Varicose Veins? <https://www.nhlbi.nih.gov/health/health-topics/topics/vv/atrisk>. Last updated 1/29/2016.
- Danielsson G, Eklof B, Grandinetti A, Kistner RL. The influence of obesity on chronic venous disease. *Vascular and endovascular surgery*. Jul-Aug 2002;36(4):271-276.
- NIH. National Heart, Lung, and Blood Institute. How Are Varicose Veins Treated? <https://www.nhlbi.nih.gov/health/health-topics/topics/vv/treatment>. Last updated 2/13/2014
- Scherger J. First Consult. Varicose Veins. www.clinicalkey.com. Last updated 6/18/2012.

Diet






- Low fiber diet ~ bowel movement strain
- Straining
 - ☞ abdominal pressure
 - ☞ venous pressure
 - ☞ venous wall strength
 - ☞ varicose veins






ACTIVITY







How Active is Active?

- Advanced chronic venous disease is associated with overall poor mobility status
- Increased mobility promotes ulcer healing and to be an adjunct to compression therapy
- Aged matched controls (> 60 years) to those with VU
 - walking speed, endurance, and self- perceived exertion were severely impaired
 - ankle plantar flexion and dorsiflexion were significantly reduced if active ulcers were present 📍 pain




Leg Elevation

- 🖱️ Venous drainage
- 🖱️ Blood return to the heart
- 🖱️ Ankle edema
- 🖱️ Cutaneous microcirculation
- 🖱️ C5 recurrence with
 - compression
 - leg elevation times of 33 minutes per day



- Abu-Own A, Scurr JH, Coleridge-Smith PD. Effect of leg elevation on the skin microcirculation in chronic venous insufficiency. *J Vasc Surg* 1994;20:705–10.
- Sindrup JH, Avnstorpe C, Steenfos HH, et al. Transcutaneous PO₂ and laser Doppler blood flow measurements in 40 patients with venous leg ulcers. *Acta Derm Venereol* 1987;67:160–3.
- <https://www.loungedoctor.com/classroom.html>

Ambulatory Venous Pressure




COMPRESSION




Rationale

- Foundation of the treatment
- Attenuate reflux-induced venous hypertension.
- Normal standing resting venous pressure \sim 60 to 80 mmHg
- Compression between 35 - 40 mmHg
- Safe limit \sim 60 mm Hg has been shown to be the safe upper limit (ABI $>$ 0.5)



Biochemical Effects



- 📌 Capillary density
- 📌 Transcutaneous oxygen
- 📌 Inflammatory cytokines
- 📌 Tumor necrosis factor α
- 📌 Endothelial growth factor
- 📌 Interleukin 1β




Table 53-5 Treatment of Venous Disorders Based on Pathophysiology

Venous Pathophysiology	Primary Treatment	Secondary Treatment*
Reflux		
Superficial	Compression	Ablation, HLS, sclerotherapy, foam, phlebectomy, pharmacologic
Deep Perforator	Compression Compression	Valve reconstruction Ablation, foam, ligation, SEPS
Obstruction (nonacute)		
Central	Compression, venous stenting	Venous stenting
Peripheral	Compression	Valve reconstruction
Muscle pump dysfunction	Compression	Structured exercise

*Ablation indicates endovenous radiofrequency and laser ablation. HLS indicates high ligation and stripping. Pharmacologic includes the micronized purified flavonoid fraction (Daflon), horse chestnut seed extract. SEPS indicates subfascial endoscopic perforator surgery. Central obstruction indicates vein segments involving the femoroiliocaval segments, and peripheral vein segments involve the femoropopliteal segments.


Lets Get Real

- Thrombo-Embolic Deterrent Hose (TED)
- Gradient compression stockings
- Anti-embolism compression stockings
- Knee-high
- Thigh-high length
- 10 to 15 mmHg



Paul Gerson Unna

- 1850 to 1929
- Private Dermatology practice
- Strong interest in venous disease
- “Unna Boot”



What is Unna's Boot?

- 4 inches wide
- 10 yards long
- Thick creamy mixture
 - zinc oxide
 - calamine
 - acacia
 - glycerin
 - castor oil and white petrolatum





INFECTION CONTROL







To Treat or Not To Treat

- Complex
- Bacterial colonization
- Superimposed bacterial infections
- Cochrane review of 22 RCTs
 - Systemic antibiotics?
 - Topical antibiotics?
 - Antiseptics?
 - No evidence that routine use of oral antibiotics improves healing




Bugs Bugs Bugs

- Staphylococcus aureus
- Pseudomonas aeruginosa
- Beta-haemolytic streptococci
- Broad spectrum penicillin
- Macrolide
- Quinolone
- Two-week course



Antibiotics




- Topical antiseptic agent cadexomer iodine - increased healing rate at four to six weeks compared with placebo.
- Oral antibiotics are recommended to treat venous ulcers only in cases of suspected cellulitis.
- Consider IV antibiotics for failed outpatient management

MEDICAL MANAGEMENT



Pentoxifylline

- Competitive nonselective inhibitor of the enzyme adenylate cyclase
 - 🖱️ intracellular cyclic adenosine monophosphate
 - 🖱️ protein kinase A
 - 🖱️ inhibition of tumor necrosis factor
 - 🖱️ leukotriene synthesis



Pentoxifylline

A factorial, randomized trial of pentoxifylline or placebo, four-layer or single-layer compression, and knitted viscose or hydrocolloid dressings for venous ulcers

E. Andrea Nelson, PhD, RN,^{1,2} Robin J. Prescott, PhD, RN,^{2,3} Douglas R. Harper, MD, BSc, FRCSEd, FRCGS,⁴ Barbara Gibson, RN,² Dorothy Brown, RN,² and C. Vaughan Buckley, MB, ChM, FRCPE, FRCSE,^{2,5} Leith and Edinburgh, United Kingdom

Objective: We evaluated the effectiveness of pentoxifylline, knitted viscose or hydrocolloid dressings, and single-layer or four-layer bandaging for venous ulceration.

Method: A factorial randomized controlled trial with 24-week follow-up was conducted in leg ulcer clinics in Scotland with blinded allocation to pentoxifylline (1200 mg) or placebo, knitted viscose or hydrocolloid dressing, and single-layer or four-layer bandage. The study enrolled 245 adults with venous ulcers. The main outcome measure was time to complete healing. Secondary outcomes included proportion healed, withdrawal, and adverse events. Analysis was by intention to treat.

Results: There was no evidence of interaction between the drug, bandage, and dressing. Pentoxifylline was associated with nonsignificant increased ulcer healing (62% vs 53%, $P = .21$). Four-layer bandage was associated with significantly higher healing rates (67% vs 49%, $P = .009$). There was no difference including between knitted viscose and hydrocolloid dressings (58% and 57%, $P = .88$). Cox regression models increased the significance of the pentoxifylline effect (relative risk of healing, 1.4; 95% confidence interval, 1.0 to 2.0).

Conclusion: Pentoxifylline increased the proportion healing compared with placebo to the same extent as ulcers in recent systematic reviews, although this finding was only statistically significant when a secondary adjusted analysis was conducted. Four-layer bandaging produced higher healing rates than single-layer bandaging. There was no difference in time to healing between knitted viscose and hydrocolloid dressing. (J Vasc Med 2007;45:134-41.)

Leg ulceration is a chronic, recurring condition affecting about 1% of the adult population in industrialized countries.¹⁻³ Most ulcers are secondary to venous insufficiency; others are due to arterial insufficiency, diabetes mellitus, rheumatoid arthritis, and connective tissue disorders. The primary functional abnormality in venous ulceration is ambulatory venous hypertension caused by venous reflux or obstruction that gives rise to changes at the tissue level, including white cell trapping, capillary stalling, and pericapillary fibrin casts.⁴ Externally applied compression, such as bandages, stockings, or pneumatic boots, reduces venous hypertension and promotes healing.⁵

A systematic review has found that compression heals more ulcers than dressing alone.⁶ It has not been possible,

however, to determine the dose-response relationship between compression levels and healing rates, and whether, for example, multiple layers of bandage are necessary.⁶ Four-layer bandaging is widely used but it can be bulky, and we sought to compare it with a single-layer bandage that can apply and store high levels of pressure.⁶

Ulcer management includes wound dressings to protect bandages from adhering to the wound and to provide a moist environment for wound healing.⁶ Modern dressings such as hydrocolloids promote moist wound healing by retaining moisture from the wound. The role of such semi-occlusive dressings in venous ulcers is unclear, however, because bandages also restrict moisture loss,⁷ and a moist wound environment can thus be achieved with a dry dressing. Hydrocolloids cost more and have higher rates of contact sensitivity than simple dressings⁸; therefore, we set out to compare the relative effectiveness of knitted viscose and hydrocolloid dressings.

Another goal was to determine whether adjustment of moisture release pentoxifylline (oxperitylline) with compression and dressing would increase healing rates, as European trials in 247 people receiving compression did not provide conclusive results.^{9,10} and one trial found a statistically significant benefit with pentoxifylline.¹¹

A factorial trial design allows examination of the interaction between interventions and comparison of a number of independent interventions with no increase in trial size.

From the School of Health and University of Leith; Leith and South Wain (Leith Venous); and the Medical Research Unit, and Department of Surgery, University of Edinburgh.

Supported by Grant No. UK01, Health Research Institute, Chief Scientist Office, Scotland.

Conflicts of interest: The trial was partly funded by the distribution of pentoxifylline (Bioscience), hydrocolloid dressings (ConvaTec), and the single-layer bandage (ConvaTec), but the authors and sponsors were not financially involved.

Correspondence: E. Andrea Nelson, PhD, RN, School of Health and Life Sciences, University of Leith, Leith 152 9JY, UK (e-mail: e.a.nelson@leith.ac.uk).


© 2007 Blackwell Publishing Ltd
Copyright © 2007 by Thieme Medical Publishers, Inc., a Division of Thieme Medical Publishers, Inc.
0891-3249/07/1502-0134-08
DOI: 10.1055/s-0106-91043

134

- Prospective randomized trial
 - 245 C₆ patients
 - Pentoxifylline 1200 mg daily
 - Standard dressings
 - Ulcer healing (62% vs 53%; p= NS)
 - Cox regression analysis model resulted in a clinically marginal significant improvement in ulcer healing in the Pentoxifylline group


Pentoxifylline

- Cochrane review
- 12 trials
- 864 patients
- Pentoxifylline plus compression was found to be more effective than compression alone
- Pentoxifylline therapy alone was more effective than placebo or no treatment




Phlebotropic



- Daflon 500
- 90% micronized Diosmin and 10% Flavonoids
- Anti-inflammatory activity with inhibition of granulocytes and macrophage infiltration in the venous parenchyma.
- Animal model
 - leukocyte adhesion/migration into valvular tissue
 - expression of intercellular adhesion molecule-1 and P-selectin
 - apoptosis of endothelial cells
 - venous valve degeneration was attenuated in the treatment group



Horse Chestnut Seed Extract




- *Aesculus hippocastanum*
- Traditional herbal remedy
- Swelling and inflammation
- Used extensively in Europe to treat venous disorders.
- RCT is an effective and safe short-term treatment for chronic venous insufficiency
- Extract contains flavonoids



- Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. The Cochrane database of systematic reviews. Nov 14 2012;11:CD003230.
- Yu Z, Su P. Effect of beta-aescin extract from Chinese buckeye seed on chronic venous insufficiency. *Die Pharmazie*. Jun 2013;68(6):428-430.
- AMR. *Aesculus hippocastanum* (Horse chestnut). Monograph. *Alternative medicine review: a journal of clinical therapeutic*. Sep 2009;14(3):278-283.
- www.amazon.com/Natures-Life-Chestnut-Extract-capsules/dp/B00014HV0W

Pycnogenol

- French maritime pine bark.
- Chronic venous insufficiency
- Venous ulcer healing
- Reducing extremity edema
- Anti-inflammatory
- Vasodilating
- Anti-thrombotic properties
- May slow progression to chronic venous insufficiency?



- Gulati OP. Pycnogenol in chronic venous insufficiency and related venous disorders. *Phytotherapy research: PTR*. Mar 2014;28(3):348-362.
- Toledo RR, Santos ME, Schneider TB. Effect of Pycnogenol on the Healing of Venous Ulcers. *Annals of vascular surgery*. 2017;38:212-219.
- Belcaro G, Dugall M, Luzzi R, Hosoi M, Corsi M. Improvements of venous tone with pycnogenol in chronic venous insufficiency: an ex vivo study on venous segments. *The International journal of angiology: official publication of the International College of Angiology, Inc*. Mar 2014;23(1):47-52.
- www.ilactr.com/ilac/daflon.html
- www.pycnogenol.com/about/faq/

Centella Asiatica




- Gotu kola
- Southeast Asia tropical plant
- Carotenoids and Vitamins C and B complex
- RCT
 - likely exerts beneficial effects on the signs and symptoms of chronic venous insufficiency
 - significantly improved edema-related symptoms in patients with venous hypertension
 - ankle edema
 - improved the capacity of veins to stretch or dilate

- Chandrika UG, Prasad Kumarab PA. Gotu Kola (Centella asiatica): Nutritional Properties and Plausible Health Benefits. *Advances in food and nutrition research*. 2015;76:125-157.
- Chong NJ, Aziz Z. A Systematic Review of the Efficacy of Centella asiatica for Improvement of the Signs and Symptoms of Chronic Venous Insufficiency. *Evidence-based complementary and alternative medicine: eCAM*. 2013;2013:627182.
- MacKay D. Hemorrhoids and varicose veins: a review of treatment options. *Alternative medicine review : a journal of clinical therapeutic*. Apr 2001;6(2):126-140.
- De Sanctis MT, Belcaro G, Incandela L, Cesarone MR, Griffin M, Ippolito E, Cacchio M. Treatment of edema and increased capillary filtration in venous hypertension with total triterpenic fraction of Centella asiatica: a clinical, prospective, placebo-controlled, randomized, dose-ranging trial. *Angiology*. Oct 2001;52 Suppl 2:S55-59.
- Pointel JP, Boccalon H, Cloarec M, Ledevhat C, Joubert M. Titrated extract of Centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. *Angiology*. Jan 1987;38(1 Pt 1):46-50.
- www.ilactr.com/ilac/daflon.html
- https://en.wikipedia.org/wiki/Centella_asiatica#/media/File:Thankuni_Herbs.jpg

Sulodexide

- Purified complex of glycosaminoglycans
- Naturally occurs in ulcers
- Anticoagulant
- Anti-inflammatory
- Improves healing
- Used in Europe



Oxerutin



- Semisynthetic flavonoids mixture
- Commonly used in Europe
- Clinical trials
 - reduced edema
 - decreased pain
- Reduce excessive venous permeability and improvement in venous micro-circulation

• Aziz Z, Tang WL, Chong NJ, Tho LY. A systematic review of the efficacy and tolerability of hydroxyethylrutosides for improvement of the signs and symptoms of chronic venous insufficiency. *J Clin Pharm Ther.* Apr 2015;40(2):177-185.

• Firuzi O, Miri R, Tavakkoli M, Saso L. Antioxidant therapy: current status and future prospects. *Current medicinal chemistry.* 2011;18(25):3871-3888.

• Wadworth AN, Faulds D. Hydroxyethylrutosides. A review of its pharmacology, and therapeutic efficacy in venous insufficiency and related disorders. *Drugs.* Dec 1992;44(6):1013-1032.

• Petruzzellis V, Troccoli T, Candiani C, Guarisco R, Lospalluti M, Belcaro G, Dugali M. Oxerutins (Venoruton): efficacy in chronic venous insufficiency—a double-blind, randomized, controlled study. *Angiology.* May-Jun 2002;53(3):257-263.


• Eberhardt RT, Raffetto JD. Chronic venous insufficiency. *Circulation.* Jul 22 2014;130(4):333-346.

• Rabe E, Stucker M, Esperester A, Schafer E, Ottilinger B. Efficacy and tolerability of a red-vine-leaf extract in patients suffering from chronic venous insufficiency—results of a double-blind placebo-controlled study. *Eur J Vasc Endovasc Surg.* Apr 2011;41(4):540-547.

• Yildiz C, Conkbayir, C, Huseynov, E. The efficiency of O-(beta-hydroxyethyl)-rutosides in reducing the incidence of superficial venous insufficiency in patients with calf muscle pump dysfunction. *Phlebology / Venous Forum of the Royal Society of Medicine.* 2016;0(0):1-6. <https://www.heise.de/preisvergleich/novartis-venoruton-gel-a1015855.html>.

Others

Compound	Comments
Vitamin E	<ul style="list-style-type: none"> Fat-soluble vitamin and free radical scavenger/anticoagulant
Grape Seed Extract	<ul style="list-style-type: none"> Proanthocyanidins Inhibit enzymes that degrade collagen and elastin efficacy in enhancing vascular function and circulation.
Vitamin C	<ul style="list-style-type: none"> Scavenger of free radicals that also contributes to venous dilation. Necessary for the synthesis of collagen important role in wound healing
Butcher's Broom	<ul style="list-style-type: none"> Ruscus aculeatus Inhibit elastase enzymes - reduces vascular permeability Contributes to edema.
Red Vine Leaf Extract	<ul style="list-style-type: none"> Leaves of the wine grape plant (<i>Vitis vinifera</i>) Powerful flavonoid present in many plants. Improves pain and sensation of heaviness and swelling







- Higdon J. Linus Pauling Institute. Micronutrient Information Center: Vitamin E.
- Brown A. Life-style advice and self-care strategies for venous leg ulcer patients: what is the evidence? J Wound Care 2012;21:342-4, 346, 348-50.
- MacKay D. Hemorrhoids and varicose veins: a review of treatment options. Alternative medicine review : a journal of clinical therapeutics. Apr 2001;6(2):126-140.
- AMR. Ruscus aculeatus (butcher's broom). Monograph. Alternative medicine review: a journal of clinical therapeutics. Dec 2001;6(6):608-612.
- Scallan J, Huxley VH, J. KR. Capillary Fluid Exchange: Regulation, Functions, and Pathology. Chapter 4: Pathophysiology of Edema Formation. San Rafael (CA): Morgan & Claypool Life Sciences; 2010. <https://www.ncbi.nlm.nih.gov/books/NBK53445>.
- Stucker M, Debus ES, Hoffmann J, Junger M, Kroger K, Mumme A, . . . Rabe E. Consensus statement on the symptom-based treatment of chronic venous diseases. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. Jun 2016;14(6):575-583.
- Rabe E, Guex JJ, Morrison N, Ramelet AA, Schuller-Petrovic S, Scuderi A, . . . Pannier F. Treatment of chronic venous disease with flavonoids: recommendations for treatment and further studies. Phlebology / Venous Forum of the Royal Society of Medicine. Sep 2013;28(6):308-319.
- Rabe E, Stucker M, Esperester A, Schafer E, Ottlinger B. Efficacy and tolerability of a red-vine-leaf extract in patients suffering from chronic venous insufficiency--results of a double-blind placebo-controlled study. Eur J Vasc Endovasc Surg. Apr 2011;41(4):540-547.
- Fernandes F, Ramalhosa, E, Pires, P, et al. Vitis vinifera leaves towards bioactivity. Industrial Crops and Products. 2013;43:434-440.

FOOD FOR THOUGHT



Venous Epidemiology

- ~ 1% Western Countries
- ~ 0.3% World Wide
- Active or healed venous ulcer
- Chronic venous disease
⬇ prevalence with age -
considered a “dose-
related risk factor”



- Kurz X, Kahn SR, Abenhaim L, et al. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence based report of the VEINES task force. Venous Insufficiency Epidemiologic and Economic Studies. *Int Angiol.* 1999;18:83-102.
- Evans CJ, Fowkes FG, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. *J Epidemiol Community Health.* 1999;53:149-153.
- Alguire PC, Mathes BM. Chronic venous insufficiency and venous ulceration. *J Gen Intern Med.* 1997;12:374-383

Prevalence

Year of publication	Reference	CVI manifestation	Prevalence (%)	
			Males	Females
1958	Arnoldi (23)	Active or healed ulcer	1.9	5.5
1966	Bobek et al. (99)	Active or healed ulcer	0.9	1.1
1969	Mekky et al. (37)	Hyperpigmentation, ulcer, edema, and eczema		10.0
1973	Coon et al. (54)	Stasis skin change**	3.0	3.7
		Active or healed ulcer	0.1	0.3
1974	DaSilva et al. (56)	Dilated subcutaneous veins	10.0	15.0
		Hyperpigmentation	8.7	9.6
		Active or healed ulcer	1.1	1.4
1978	Widmer (20)	Skin changes*	6.0	5.0
		Active or healed ulcer	1.0	1.0
1986	Maffei et al. (53)	Edema	17.1	20.3
		Hyperpigmentation	7.6	5.2
		Eczema	2.5	1.1
		Fibrosis	1.3	0.5
		Active or healed ulcer	2.5	4.1
1992	Franks et al. (60)	Active or healed ulcer	4.7	4.0
1994	Komsuoglu et al. (42)	Hyperpigmentation	0.3	2.8
		Eczema	0.5	1.8
		Active or healed ulcer	0.6	1.4
1999	Evans et al. (21)	Dilated subcutaneous veins	6.9	5.3
2002	Ruckley et al. [†] (32)	Hyperpigmentation	1.3	1.1
		Active or healed ulcer	1.0	0.2
2003	Criqui et al. (40)	Trophic changes [‡]	7.8	5.3
		Edema	7.4	4.9


*Excluding varicose veins.




**Hyperpigmentation, fibrosis, induration, atrophy.

[†]Edinburgh Vein Study (results published in two manuscripts).


[‡]Hyperpigmentation, lipodermatosclerosis, ulcer.


Venous Epidemiology

- Around 400,000 to 600,000 venous ulcers affect the US population
- Rarely fatal and hardly ever progress to amputation  frequent hospitalizations
- 37% to 48% recurrence rate of healed venous stasis wounds at 3 years





- Valencia IC, Falabella A, Kirsner RS, Eaglstein WH. Chronic venous insufficiency and venous leg ulceration. *J Am Acad Dermatol* 2001; 44: 401-424.
- McDaniel HB, Marston WA, Farber MA, et al. Recurrence of chronic venous ulcers on the basis of clinical, etiologic, anatomic, and pathophysiologic criteria and air plethysmography. *J Vasc Surg* 2002;35: 723-728.
- Erickson CA, Lanza DJ, Karp DL, et al. Healing of venous ulcers in an ambulatory care program: the roles of chronic venous insufficiency and patient compliance. *J Vasc Surg* 1995;22:629-636.





Percutaneous Valves




Genes

Table 1 – Reports of genetic mutations associated with poor healing and progression of venous leg ulcers.

Study	Type of genetic defect	Phenotypic change	Clinical effect
Toganzzo, 2006 [42]	F13A1 gene	Factor XIII deficiency	Delay in healing of venous ulcers
Zamboni, 2006 [43]	HFE gene	Increased iron deposition	Exacerbation of venous ulcers
Sam, 2003 [44]	MTFR gene (SNP C677T)	Reduction in enzyme methylenetetrahydrofolate reductase function	Associated with varicose veins and chronic venous disease (CEAP score 4–6)
Sverdlova, 1998 [45]			
Gemmati, 2009 [46]	SLC40A1 (SNP 8CG)	Possible increased iron deposition	Increased the risk of chronic venous disease and primary leg ulcer development
Gemmati, 2009 [46]	MMP-12 (SNP 82AA)	Functional change	Increased risk of ulcer formation
Nagy, 2005 [47]	FGFR-2 (SNP 2451 AG)	Possible messenger RNA instability-reduced mitogenesis	Associated with nonhealing ulcers

Adapted from Anwar et al [10], with permission.
CEAP, clinical, etiology, anatomy, pathophysiology.




Psychological Impact

- 81% patients with venous stasis ulcers experience decreased mobility
- 57% of patients report severely limited mobility
- 68% with fear, anger, depression and social isolation



CONCLUSIONS





HAMPDEN SYDNEY COLLEGE

Lectures on Surgery



B. Warner M.D.


W. Aug. Hopkins Richmond Session 1858-59



to bind up the nation's wounds, to care for him who shall have borne the battle and for his widow, and his orphan, to do all which may achieve and cherish a just and lasting peace among ourselves and with all nations."



michael.amendola@va.gov



References

- Fort F. Venous Insufficiency, Chronic. In: Ferri FF, ed. *Ferri's Clinical Advisor 2017*: Elsevier, Inc.; 2017.
- Eberhardt RT, Raffetto JD. Chronic venous insufficiency. *Circulation*. Jul 22 2014;130(4):333-346.
- NIH. National Heart, Lung, and Blood Institute. Who Is at Risk for Varicose Veins? <https://www.nhlbi.nih.gov/health/health-topics/topics/vv/atrisk>. Last updated 1/29/2016.
- Danielsson G, Eklof B, Grandinetti A, Kistner RL. The influence of obesity on chronic venous disease. *Vascular and endovascular surgery*. Jul-Aug 2002;36(4):271-276.
- NIH. National Heart, Lung, and Blood Institute. How Are Varicose Veins Treated? <https://www.nhlbi.nih.gov/health/health-topics/topics/vv/treatment>. Last updated 2/13/2014
- Scherger J. First Consult. Varicose Veins. www.clinicalkey.com. Last updated 6/18/2012.
- MacKay D. Hemorrhoids and varicose veins: a review of treatment options. *Alternative medicine review : a journal of clinical therapeutic*. Apr 2001;6(2):126-140.




References

- Threapleton DE, Greenwood DC, Evans CE, Cleghorn CL, Nykjaer C, Woodhead C, Burley VJ. Dietary fiber intake and risk of cardiovascular disease: systematic review and meta-analysis. *BMJ (Clinical research ed.)*. Dec 19 2013;347:f6879.
- Beidler SK, Douillet CD, Berndt DF, et al. Inflammatory cytokine levels in chronic venous insufficiency ulcer tissue before and after compression therapy. *J Vasc Surg* 2009;49: 1013–20.
- Partsch B, Partsch H. Calf compression pressure required to achieve venous closure from supine to standing positions. *J Vasc Surg* 2005;42:734–8.
- Aziz Z, Tang WL, Chong NJ, Tho LY. A systematic review of the efficacy and tolerability of hydroxyethylrutosides for improvement of the signs and symptoms of chronic venous insufficiency. *J Clin Pharm Ther*. Apr 2015;40(2):177-185.
- Firuzi O, Miri R, Tavakkoli M, Saso L. Antioxidant therapy: current status and future prospects. *Current medicinal chemistry*. 2011;18(25):3871-3888.
- Wadworth AN, Faulds D. Hydroxyethylrutosides. A review of its pharmacology, and therapeutic efficacy in venous insufficiency and related disorders. *Drugs*. Dec 1992;44(6):1013-1032.



References

- Petruzzellis V, Troccoli T, Candiani C, Guarisco R, Lospalluti M, Belcaro G, Dugall M. Oxerutins (Venoruton): efficacy in chronic venous insufficiency--a double-blind, randomized, controlled study. *Angiology*. May-Jun 2002;53(3):257-263.
- Eberhardt RT, Raffetto JD. Chronic venous insufficiency. *Circulation*. Jul 22 2014;130(4):333-346.
- Rabe E, Stucker M, Esperester A, Schafer E, Ottillinger B. Efficacy and tolerability of a red-vine-leaf extract in patients suffering from chronic venous insufficiency--results of a double-blind placebo-controlled study. *Eur J Vasc Endovasc Surg*. Apr 2011;41(4):540-547.
- Yildiz C, Conkbayir, C, Huseynov, E. The efficiency of O-(beta-hydroxyethyl)-rutosides in reducing the incidence of superficial venous insufficiency in patients with calf muscle pump dysfunction. *Phlebology / Venous Forum of the Royal Society of Medicine*. 2016;0(0):1-6.
- Aziz Z, Tang WL, Chong NJ, Tho LY. A systematic review of the efficacy and tolerability of hydroxyethylrutosides for improvement of the signs and symptoms of chronic venous insufficiency. *J Clin Pharm Ther*. Apr 2015;40(2):177-185.
- Firuzi O, Miri R, Tavakkoli M, Saso L. Antioxidant therapy: current status and future prospects. *Current medicinal chemistry*. 2011;18(25):3871-3888.



References

- Wu B, Lu J, Yang M, Xu T. Sulodexide for treating venous leg ulcers. The Cochrane database of systematic reviews. Jun 02 2016(6):CD010694.
- Eberhardt RT, Raffetto JD. Chronic venous insufficiency. Circulation. Jul 22 2014;130(4):333-346.
- Coccheri S, Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug design, development and therapy. 2014;8:49-65.
- <https://pubchem.ncbi.nlm.nih.gov/compound/14366984>
- Wadworth AN, Faulds D. Hydroxyethylrutosides. A review of its pharmacology, and therapeutic efficacy in venous insufficiency and related disorders. Drugs. Dec 1992;44(6):1013-1032.
- Petruzzellis V, Troccoli T, Candiani C, Guarisco R, Lospalluti M, Belcaro G, Dugall M. Oxerutins (Venoruton): efficacy in chronic venous insufficiency--a double-blind, randomized, controlled study. Angiology. May-Jun 2002;53(3):257-263.
- Eberhardt RT, Raffetto JD. Chronic venous insufficiency. Circulation. Jul 22 2014;130(4):333-346.



References

- Rabe E, Stucker M, Esperester A, Schafer E, Ottilinger B. Efficacy and tolerability of a red-vine-leaf extract in patients suffering from chronic venous insufficiency--results of a double-blind placebo-controlled study. *Eur J Vasc Endovasc Surg*. Apr 2011;41(4):540-547.
- Yildiz C, Conkbayir, C, Huseynov, E. The efficiency of O-(beta-hydroxyethyl)-rutosides in reducing the incidence of superficial venous insufficiency in patients with calf muscle pump dysfunction. *Phlebology / Venous Forum of the Royal Society of Medicine*. 2016;0(0):1-6.
- <https://www.heise.de/preisvergleich/novartis-venoruton-gel-a1015855.html>
- Higdon J. Linus Pauling Institute. Micronutrient Information Center: Vitamin E.
- Brown A. Life-style advice and self-care strategies for venous leg ulcer patients: what is the evidence? *J Wound Care* 2012;21:342–4, 346, 348–50.
- MacKay D. Hemorrhoids and varicose veins: a review of treatment options. *Alternative medicine review : a journal of clinical therapeutic*. Apr 2001;6(2):126-140.
- AMR. *Ruscus aculeatus* (butcher's broom). Monograph. *Alternative medicine review: a journal of clinical therapeutic*. Dec 2001;6(6):608-612.



References

- Stucker M, Debus ES, Hoffmann J, Junger M, Kroger K, Mumme A, . . . Rabe E. Consensus statement on the symptom-based treatment of chronic venous diseases. *Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG*. Jun 2016;14(6):575-583.
- Rabe E, Guex JJ, Morrison N, Ramelet AA, Schuller-Petrovic S, Scuderi A, . . . Pannier F. Treatment of chronic venous disease with flavonoids: recommendations for treatment and further studies. *Phlebology / Venous Forum of the Royal Society of Medicine*. Sep 2013;28(6):308-319.
- Rabe E, Stucker M, Esperester A, Schafer E, Ottillinger B. Efficacy and tolerability of a red-vine-leaf extract in patients suffering from chronic venous insufficiency--results of a double-blind placebo-controlled study. *Eur J Vasc Endovasc Surg*. Apr 2011;41(4):540-547.
- Fernandes F, Ramalhosa, E, Pires, P, et al. *Vitis vinifera* leaves towards bioactivity. *Industrial Crops and Products*. 2013;43:434-440.
- Chandrika UG, Prasad Kumarab PA. Gotu Kola (*Centella asiatica*): Nutritional Properties and Plausible Health Benefits. *Advances in food and nutrition research*. 2015;76:125-157.



References

- Chong NJ, Aziz Z. A Systematic Review of the Efficacy of *Centella asiatica* for Improvement of the Signs and Symptoms of Chronic Venous Insufficiency. Evidence-based complementary and alternative medicine: eCAM.2013;2013:627182.
- MacKay D. Hemorrhoids and varicose veins: a review of treatment options. Alternative medicine review : a journal of clinical therapeutic. Apr 2001;6(2):126-140.
- De Sanctis MT, Belcaro G, Incandela L, Cesarone MR, Griffin M, Ippolito E, Cacchio M. Treatment of edema and increased capillary filtration in venous hypertension with total triterpenic fraction of *Centella asiatica*: a clinical, prospective, placebo-controlled, randomized, dose-ranging trial. Angiology. Oct 2001;52 Suppl 2:S55-59.
- Pointel JP, Boccalon H, Cloarec M, Ledevhat C, Joubert M. Titrated extract of *Centella asiatica* (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology. Jan 1987;38(1 Pt 1):46-50.
- www.ilactr.com/ilac/daflon.html
- https://en.wikipedia.org/wiki/Centella_asiatica#/media/File:Thankuni_Herbs.jpg

